Autolus Therapeutics stock tumbles ~20% after hours as co files for stock offering

Autolus Therapeutics (NASDAQ:AUTL) on Thursday said it had commenced a public offering of its American depositary shares.
U.S.-listed shares of AUTL fell 20.7% to $2.37 in aftermarket trading.
The size of the proposed offering was yet to be determined.
AUTL after hours separately announced that an interim analysis of a phase 2 trial of its investigational CAR-T cell therapy obe-cel for the treatment of a type of blood cancer found that the study met its main goal.
Additionally, AUTL said that it would get $70M in milestone payments from Blackstone Life Sciences.